Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
HYPERION THERAPEUTICS INC (HPTX)
|
Add to portfolio |
|
|
|
| Price: |
$45.99
| | Metrics |
| OS: |
21.0
|
M
| |
-1
|
% ROE
|
| Market cap: |
$965
|
M
| |
47
|
% ROIC
|
|
Net cash:
|
$137
|
M
| |
$6.53
|
per share
|
|
EV:
|
$828
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$37.8
|
M
| |
21.9
|
x EV/EBITDA
|
|
EBIT
|
$28.3
|
M
| |
29.3
|
x EV/EBIT
|
| EPS |
($0.11)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-14 | Dec-31-13 | Dec-31-12 | Nov-01-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 |
| Revenues | 113.6 | 42.2 | 28.8 | | 26.6 | 0.0 | 0.0 | 0.0 |
| Revenue growth | 169.1% | 46.4% | 8.6% | | | | | |
| Cost of goods sold | 13.7 | 6.7 | 0.0 | | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 99.9 | 35.5 | 28.8 | | 26.6 | 0.0 | 0.0 | 0.0 |
| Gross margin | 87.9% | 84.0% | 100.0% | | 100.0% | | | |
| Selling, general and administrative | 48.5 | 35.8 | 11.5 | | 8.9 | | | 0.0 |
| Sales and marketing | | | | | | 0.8 | 0.5 | 0.0 |
| Research and development | 20.7 | 10.0 | 17.0 | | 17.2 | 23.1 | 11.0 | |
| General and administrative | | | | | | 2.7 | 1.9 | 0.0 |
| EBITA | 30.6 | -10.4 | -28.5 | | -26.2 | -26.6 | -13.4 | 0.0 |
| EBITA margin | 27.0% | -24.5% | -99.0% | | -98.5% | | | |
| Amortization of intangibles | 4.6 | 3.1 | | | | | | |
| EBIT | 26.0 | -13.4 | -28.5 | | -26.2 | -26.6 | -13.4 | 0.0 |
| EBIT margin | 22.9% | -31.8% | -99.0% | | -98.5% | | | |
| Pre-tax income | -6.0 | 16.7 | -32.3 | | -29.4 | -25.5 | -13.6 | -29.1 |
| Income taxes | 0.3 | 0.0 | 0.0 | | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | 0.3% | 0.0% | | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -6.3 | 16.6 | -32.3 | | -29.4 | 0.0 | 0.0 | -29.1 |
| Net margin | -5.5% | 39.4% | -111.9% | | -110.8% | | | |
| |
| Diluted EPS | ($0.31) | $0.80 | ($4.45) | | ($62.68) | | | |
| Shares outstanding (diluted) | 20.5 | 20.7 | 7.3 | | 0.5 | | | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|